Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
In this study, we performed a systematic review and meta-analysis of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension (CHD-PAH) to evaluate its safety and tolerability. Online electronic database including PubMed, EMBASE and Springer were searched from October 2006 to October 2013 to collect the clinical studies or cohort trials on CHD-PAH with bosentan treatment. Weight Mean Difference (WMD) and Standard Mean Difference (SMD) were used to evaluate the treatment safety and tolerability. Review Manager (RevMan) version 5.0 was performed for the data analysis. Totally 8 studies including 215 patients with CHD-PAH were enrolled in this research. With a period of 3-6 months oral bosentan treatment in patients, there were no significant differences in the scores of resting oxygen saturation (Resting SpO2), post-6-MWT SpO2 after 6-minutes' walktest (6-MWT) and Borg dyspnea index score (BDIs) compared with the baseline; the walking distance on 6-MWT increased significantly. With a period of one year or more oral bosentan treatment, the scores of resting SpO2 and post-6-MWT SpO2 increased significantly; there was no significant difference in BDIs and walking distance on 6-MWT. The short-term treatment with oral bosentan could increase walking distance on 6-MWT, and long-term treatment could increase the Resting SpO2 in CHD-PAH patients. Oral bosentan in CHD-PAH patients was safe and well tolerated.